+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Group A & C Meningococcal Polysaccharide Vaccine Market - Global Forecast 2025-2030- Product Image
Group A & C Meningococcal Polysaccharide Vaccine Market - Global Forecast 2025-2030- Product Image
Sale

Group A & C Meningococcal Polysaccharide Vaccine Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6134270
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Group A & C Meningococcal Polysaccharide Vaccine market is evolving in response to shifting public health strategies, manufacturing innovations, and complex regulatory environments. Senior leaders looking to navigate this sector require actionable insights into supply chain resilience, innovation pathways, and global adoption trends to inform investment and operational decisions.

Market Snapshot: Group A & C Meningococcal Polysaccharide Vaccine

The Group A & C Meningococcal Polysaccharide Vaccine market is shaped by expanding preventive healthcare initiatives and rising immunization efforts worldwide. With increasing global mobility, both routine immunization schedules and emergency outbreak responses now rely on this vaccine platform. Market growth is fueled by public and private sector investments focused on optimizing supply chains and expanding distribution networks, while regulatory harmonization continues to facilitate wider cross-border deployment and foster global competition.

Scope & Segmentation

Industry stakeholders benefit from a comprehensive breakdown across end users, channels, applications, and geographies, empowering precise strategic targeting:

  • End Users: Clinics, hospitals, and public health centers, each with distinct procurement and administration preferences.
  • Distribution Channels: Hospital pharmacies, online pharmacies, and retail pharmacies support a spectrum of access points, from mass campaigns to individual travel immunizations.
  • Sales Types: Private sector and public sector agreements, reflecting varied volume commitments and value-based contract models.
  • Applications: Emergency vaccination, routine immunization, and travel vaccination, each requiring tailored distribution logistics and inventory management.
  • Administration Routes: Intramuscular and subcutaneous, impacting storage and skill requirements for healthcare providers.
  • Formulations: Liquid and lyophilized, meeting diverse healthcare setting needs and cold chain capacities.
  • Geographies: Americas (including the United States, Canada, Mexico, Brazil, and Argentina), Europe/Middle East/Africa (notably the United Kingdom, Germany, France, Russia, and South Africa), and Asia-Pacific (with a focus on China, India, Japan, Australia, and Southeast Asian nations).
  • Key Companies: Major market participants include Sanofi S.A., GlaxoSmithKline plc, Serum Institute of India, Bharat Biotech, Cadila Healthcare, Panacea Biotec, PT Bio Farma, Anhui Zhifei Longcom, Hualan Biological, and China National Pharmaceutical Group.

Key Takeaways for Decision-Makers

  • Stakeholders are focusing on supply chain optimization and cold chain resilience to address epidemic and endemic meningococcal transmission worldwide.
  • Manufacturers have accelerated R&D investment to advance polysaccharide-protein conjugation and scalable production processes, improving immunogenicity and durability.
  • Strategic alliances and technology transfers are enabling regional manufacturers to strengthen local production capacity and reduce reliance on external supply.
  • Procurement strategies are increasingly adapting to funding mechanisms that prioritize rapid access during outbreaks and regional self-sufficiency.
  • Digital tools for tracking immunization coverage bolster real-time supply management and cold chain monitoring, supporting robust campaign execution.
  • Public-private partnerships underpin competitive positioning by facilitating clinical studies, supporting tender processes, and advancing global distribution reach.

Tariff Impact: Navigating U.S. Policy Shifts

The implementation of United States tariffs in 2025 has led to increased costs for raw materials, reagents, and packaging, compelling manufacturers to reassess sourcing and develop alternative procurement strategies. These tariffs foster discussion around vertical integration, encouraging vaccine producers to invest in onshore capabilities and supply resilience. The longer-term outcome is a shift in competitive structures and strategic priorities for industry players adapting their pricing and operational models to new regulatory realities.

Methodology & Data Sources

This report utilizes a multi-stage research approach, starting with secondary analysis of regulatory frameworks, manufacturing benchmarks, and policy landscapes. Structured interviews with manufacturers, regulators, public health authorities, and procurement experts provided additional perspective. Triangulation techniques and analytical frameworks such as SWOT and PESTEL validated key trends and segmented market dynamics.

Why This Report Matters

  • Enables informed decision-making on investment, development, and distribution priorities by detailing evolving market drivers and competitive strategies.
  • Empowers stakeholders to mitigate risks tied to regulatory changes, tariffs, and shifting procurement paradigms across all regions.
  • Supports strategic alignment across public and private sectors to accelerate vaccine adoption, optimize supply chains, and scale production efficiently.

Conclusion

The Group A & C Meningococcal Polysaccharide Vaccine market remains vital as stakeholders recalibrate strategies to address supply chain challenges, technological shifts, and regulatory developments. Forward-looking organizations prioritizing collaboration and resilience will be best positioned for sustainable impact and growth.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increased adoption of conjugate meningococcal vaccines reducing long-term reliance on standalone polysaccharide formulations
5.2. Rising government-led immunization campaigns in sub-Saharan Africa boosting procurement of group A and C polysaccharide vaccines
5.3. Supply chain volatility and stringent cold chain requirements posing distribution challenges in remote regions
5.4. Intensified price competition from biosimilar vaccine manufacturers pressuring margins of established polysaccharide producers
5.5. Implementation of WHO emergency stockpile initiatives influencing procurement strategies in low-income countries
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Group A & C Meningococcal Polysaccharide Vaccine Market, by End User
8.1. Introduction
8.2. Clinics
8.3. Hospital
8.4. Public Health Centers
9. Group A & C Meningococcal Polysaccharide Vaccine Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Group A & C Meningococcal Polysaccharide Vaccine Market, by Sales Type
10.1. Introduction
10.2. Private Sector
10.3. Public Sector
11. Group A & C Meningococcal Polysaccharide Vaccine Market, by Application
11.1. Introduction
11.2. Emergency Vaccination
11.2.1. Mass Vaccination Campaigns
11.2.2. Outbreak Response
11.3. Routine Immunization
11.4. Travel Vaccination
12. Group A & C Meningococcal Polysaccharide Vaccine Market, by Administration Route
12.1. Introduction
12.2. Intramuscular
12.3. Subcutaneous
13. Group A & C Meningococcal Polysaccharide Vaccine Market, by Formulation
13.1. Introduction
13.2. Liquid
13.3. Lyophilized
14. Americas Group A & C Meningococcal Polysaccharide Vaccine Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Group A & C Meningococcal Polysaccharide Vaccine Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Group A & C Meningococcal Polysaccharide Vaccine Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Sanofi S.A.
17.3.2. GlaxoSmithKline plc
17.3.3. Serum Institute of India Private Limited
17.3.4. Bharat Biotech International Limited
17.3.5. Cadila Healthcare Limited
17.3.6. Panacea Biotec Limited
17.3.7. PT Bio Farma (Persero)
17.3.8. Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.
17.3.9. Hualan Biological Engineering Inc.
17.3.10. China National Pharmaceutical Group Co., Ltd.
18. ResearchAI19. ResearchStatistics20. ResearchContacts21. ResearchArticles22. Appendix
List of Figures
FIGURE 1. GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET: RESEARCHAI
FIGURE 28. GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET: RESEARCHSTATISTICS
FIGURE 29. GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET: RESEARCHCONTACTS
FIGURE 30. GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRIVATE SECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRIVATE SECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PUBLIC SECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PUBLIC SECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY MASS VACCINATION CAMPAIGNS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY MASS VACCINATION CAMPAIGNS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY OUTBREAK RESPONSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY OUTBREAK RESPONSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ROUTINE IMMUNIZATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ROUTINE IMMUNIZATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY TRAVEL VACCINATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY TRAVEL VACCINATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY LIQUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY LYOPHILIZED, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 89. CANADA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 90. CANADA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 91. CANADA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 92. CANADA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 93. CANADA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2018-2024 (USD MILLION)
TABLE 94. CANADA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2025-2030 (USD MILLION)
TABLE 95. CANADA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 96. CANADA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 97. CANADA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2018-2024 (USD MILLION)
TABLE 98. CANADA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2025-2030 (USD MILLION)
TABLE 99. CANADA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 100. CANADA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 101. CANADA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 102. CANADA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 103. MEXICO GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. MEXICO GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. MEXICO GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. MEXICO GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. MEXICO GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2018-2024 (USD MILLION)
TABLE 108. MEXICO GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2025-2030 (USD MILLION)
TABLE 109. MEXICO GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 110. MEXICO GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 111. MEXICO GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2018-2024 (USD MILLION)
TABLE 112. MEXICO GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2025-2030 (USD MILLION)
TABLE 113. MEXICO GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 114. MEXICO GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 115. MEXICO GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 116. MEXICO GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2025-2030 (USD MILLION)
TABLE 137. ARGENTINA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 138. ARGENTINA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2025-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. UNITED KINGDOM GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. UNITED KINGDOM GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2018-2024 (USD MILLION)
TABLE 166. UNITED KINGDOM GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2025-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 168. UNITED KINGDOM GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 175. GERMANY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. GERMANY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. GERMANY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. GERMANY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. GERMANY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2018-2024 (USD MILLION)
TABLE 180. GERMANY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2025-2030 (USD MILLION)
TABLE 181. GERMANY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 182. GERMANY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 183. GERMANY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2018-2024 (USD MILLION)
TABLE 184. GERMANY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2025-2030 (USD MILLION)
TABLE 185. GERMANY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 186. GERMANY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 187. GERMANY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 188. GERMANY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 189. FRANCE GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. FRANCE GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. FRANCE GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. FRANCE GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. FRANCE GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2018-2024 (USD MILLION)
TABLE 194. FRANCE GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2025-2030 (USD MILLION)
TABLE 195. FRANCE GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 196. FRANCE GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 197. FRANCE GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2018-2024 (USD MILLION)
TABLE 198. FRANCE GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2025-2030 (USD MILLION)
TABLE 199. FRANCE GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 200. FRANCE GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 201. FRANCE GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 202. FRANCE GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 203. RUSSIA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. RUSSIA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. RUSSIA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. RUSSIA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. RUSSIA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2018-2024 (USD MILLION)
TABLE 208. RUSSIA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2025-2030 (USD MILLION)
TABLE 209. RUSSIA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 210. RUSSIA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 217. ITALY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. ITALY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. ITALY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. ITALY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. ITALY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2018-2024 (USD MILLION)
TABLE 222. ITALY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2025-2030 (USD MILLION)
TABLE 223. ITALY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 224. ITALY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 225. ITALY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2018-2024 (USD MILLION)
TABLE 226. ITALY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2025-2030 (USD MILLION)
TABLE 227. ITALY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 228. ITALY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 229. ITALY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 230. ITALY GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 231. SPAIN GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. SPAIN GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. SPAIN GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. SPAIN GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. SPAIN GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2018-2024 (USD MILLION)
TABLE 236. SPAIN GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2025-2030 (USD MILLION)
TABLE 237. SPAIN GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 238. SPAIN GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 239. SPAIN GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2018-2024 (USD MILLION)
TABLE 240. SPAIN GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2025-2030 (USD MILLION)
TABLE 241. SPAIN GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 242. SPAIN GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 243. SPAIN GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 244. SPAIN GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2018-2024 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SALES TYPE, 2025-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2018-2024 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY EMERGENCY VACCINATION, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES GROUP A & C MENINGOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Group A & C Meningococcal Polysaccharide Vaccine Market report include:
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Serum Institute of India Private Limited
  • Bharat Biotech International Limited
  • Cadila Healthcare Limited
  • Panacea Biotec Limited
  • PT Bio Farma (Persero)
  • Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.
  • Hualan Biological Engineering Inc.
  • China National Pharmaceutical Group Co., Ltd.

Related Topics

Related Reports

Meningococcal Vaccines Market Report by Vaccine Type, Composition, Vaccine Serotype, Distribution Channel, End User, and Region 2025-2033 - Product Image

Meningococcal Vaccines Market Report by Vaccine Type, Composition, Vaccine Serotype, Distribution Channel, End User, and Region 2025-2033

  • Report
  • 146 Pages
  • Global
From
Meningococcal Disease Vaccine Global Market Report 2025 - Product Image

Meningococcal Disease Vaccine Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Meningococcal Vaccines Market Report and Forecast 2024-2032 - Product Image

Meningococcal Vaccines Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Meningococcal Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Meningococcal Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Meningococcal Vaccines Market Report 2025 - Product Image

Meningococcal Vaccines Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.